Earnings ·
Immunic reported a net loss of $34.1 million ($0.80 per share) for the second quarter ended June 30, 2026, compared to…
IMUXImmunic, Inc.
Immunic reported a net loss of $34.1 million ($0.80 per share) for the second quarter ended June 30, 2026, compared to a $26.8 million loss in the prior year period. Total operating expenses rose to $35.3 million from $27.1 million, driven by increased R&D and G&A costs. The company holds $155.1 million in cash and expects funding into late 2027. On August 6, 2026, the board appointed Elena Ridloff as a Class I director to strengthen financial expertise ahead of pivotal Phase 3 ENSURE trial data expected by year-end for its lead drug vidofludimus calcium in relapsing multiple sclerosis. Concurrently, Dr. Daniel Vitt resigned from the Board and terminated his employment with the Company Subsidiary under a separation agreement providing approximately $946,375 in severance payments plus a €15,000 monthly consulting retainer. Immunic is a late-stage biotechnology company pioneering novel oral therapies for neurologic diseases.